A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 2.25 USD 7.14% Market Closed
Market Cap: 81.4m USD
Have any thoughts about
Armata Pharmaceuticals Inc?
Write Note

Armata Pharmaceuticals Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Armata Pharmaceuticals Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Non-Reccuring Items
-$1.6B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Non-Reccuring Items
-$10B
CAGR 3-Years
-242%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Non-Reccuring Items
$243m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Non-Reccuring Items
-$4.6B
CAGR 3-Years
N/A
CAGR 5-Years
-175%
CAGR 10-Years
-51%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Non-Reccuring Items
-$219.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-35%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
81.4m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
1.61 USD
Overvaluation 28%
Intrinsic Value
Price
A

See Also

Back to Top